EPIBRAIN – Epidemiologically scaled imaging and biology for brain health across the lifespan
The McGill Genome Centre (MGC) and the University of Bordeaux (UBx) have established a far-reaching collaboration to apply advanced brain imaging in conjunction with genomics and other large-scale biology with the intent of identifying markers of neurodegenerative and vascular disease as precursors of cognitive decline and dementia, and finding new avenues for the diagnosis, prevention and treatment of these conditions. With our collaborators at the Bonn Helmholtz DZNE laboratory and University of Toronto (UT), the HBHL EPIBRAIN project will leverage on-going investments in unique population cohorts to create comprehensive datasets that integrate MRI, extensive epidemiological and health information, cognitive testing, and large-scale biological characterisations (genomics, epigenomics, metabolomics, proteomics) across the lifespan from adolescence to late old age. These datasets will provide an important infrastructure to investigate multiple facets of brain health including cognition, brain-related disease outcomes such as dementia and stroke, psychiatric disorders, addictive behaviours, and language development, and they will furnish many multi-disciplinary training opportunities for students and post-doctoral scientists.
|Mark Lathrop||McGill University||Canada|
|Stephanie Debette||University of Bordeaux||France|
|Monique Breteler||German Center for Neurodegenerative Diseases||Germany|
|Zdenka Pausova||University of Toronto||Canada|